Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3261638 | 0.77 | TSHR (0.52) | KDM4ETSHRL3MBTL1LMNAALDH1A1 | |
| SCHEMBL23009977 | 0.76 | TSHR (0.41) | KDM4ETSHRALDH1A1HSD17B10TBXAS1 | |
| SCHEMBL20915037 | 0.76 | TSHR (0.38) | KDM4ETSHRPDK2L3MBTL1ALDH1A1 | |
| SCHEMBL17786779 | 0.76 | TSHR (0.49) | KDM4ETSHRL3MBTL1LMNAALDH1A1 | |
| SCHEMBL21804494 | 0.76 | TSHR (0.49) | KDM4ETSHRALDH1A1HSD17B10TBXAS1 | |
| SCHEMBL20029632 | 0.76 | MEN1 (0.35) | KDM4EPDK2L3MBTL1LMNAMAPK1 | |
| SCHEMBL21805554 | 0.75 | TSHR (0.47) | KDM4ETSHRL3MBTL1LMNAMAPK1 | |
| SCHEMBL21804283 | 0.75 | TSHR (0.47) | KDM4ETSHRL3MBTL1LMNAMAPK1 | |
| SCHEMBL23009924 | 0.75 | TDP1 (0.48) | KDM4ETSHRL3MBTL1LMNAALDH1A1 | |
| SCHEMBL23009920 | 0.74 | TSHR (0.38) | KDM4ETSHRL3MBTL1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-07 | — | — | US | disclosed |
| EP-3697774-B1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARMA (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-16 | — | — | US | disclosed |
| CN-111757874-B | Methods for preparing modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20240025877-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-01-25 | — | — | US | disclosed |
| US-20240025877-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-01-25 | — | — | US | disclosed |
| US-11465985-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220306606-A1 | MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2022-09-29 | — | — | US | disclosed |
| CN-109803962-B | Modulators of cystic fibrosis transmembrane conductance regulator proteins, and pharmaceutical compositions | 弗特克斯药品有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-11186566-B2 | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| US-10654829-B2 | Crystalline forms and compositions of CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-19 | — | — | US | disclosed |
| US-10570115-B2 | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-02-25 | — | — | US | disclosed |
| WO-2019113476-A2 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113476-A2 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019079760-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019079760-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190119253-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARAMCEUTICALS INCORPORATED (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190119253-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARAMCEUTICALS INCORPORATED (US) | 2019-04-25 | — | — | US | disclosed |
| WO-2018064632-A1 | MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-04-05 | — | — | WO | disclosed |
| US-20180093969-A1 | Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | VERTEX PHARMACEUTICALS INCORPORATED | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570115-B2 | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | CFTR, SLC26A4, ABCB11 | KDM4E 3871/4885TSHR 1168/4885PDK2 2909/4885 |
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, SLC26A3 | KDM4E 1638/4885TSHR 1602/4885PDK2 4225/4885 |
| US-20180093969-A1 | Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator | CFTR, SLC26A4, ABCB11 | KDM4E 3871/4885TSHR 1168/4885PDK2 2909/4885 |
| US-11186566-B2 | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | CFTR, SLC26A4, ABCB11 | KDM4E 3871/4885TSHR 1168/4885PDK2 2909/4885 |
| US-20240025877-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SCNN1G | KDM4E 4464/4885TSHR 2866/4885PDK2 3402/4885 |
| US-20190119253-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | CFTR, SLC26A4, ABCC4 | KDM4E 4599/4885TSHR 3212/4885PDK2 4392/4885 |
| US-11465985-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SCNN1G | KDM4E 4286/4885TSHR 2590/4885PDK2 3484/4885 |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SCNN1G | KDM4E 4464/4885TSHR 2866/4885PDK2 3402/4885 |
| US-10654829-B2 | Crystalline forms and compositions of CFTR modulators | CFTR, SLC26A4, ABCC4 | KDM4E 4781/4885TSHR 3141/4885PDK2 4464/4885 |
| US-20220306606-A1 | MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | CFTR, SLC26A4, ABCB11 | KDM4E 3871/4885TSHR 1168/4885PDK2 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.